David Altshuler - Feb 24, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Joy Liu, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 24, 2023
Transactions value $
-$2,366,256
Form type
4
Date filed
2/28/2023, 03:40 PM
Previous filing
Feb 22, 2023
Next filing
Aug 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability -$1.15M -3.97K -9.86% $289.12 36.3K Feb 24, 2023 Direct
transaction VRTX Common Stock Sale -$1.04M -3.64K -10.02% $287.23 32.6K Feb 27, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$86.6K -300 -0.92% $288.74 32.3K Feb 27, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$87.5K -302 -0.93% $289.60 32K Feb 27, 2023 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $287.23 (range $286.80 to $287.72).
F4 Open market sales reported on this line occurred at a weighted average price of $288.74 (range $288.42 to $289.37).
F5 Open market sales reported on this line occurred at a weighted average price of $289.60 (range $289.49 to $289.65).